Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy

Published:2016-09 Issue:9 Volume:28 Page:1412-1421
ISSN:0898-6568
Container-title:Cellular Signalling
language:en
Short-container-title:Cellular Signalling

Author:

Grzmil Michal,Seebacher Jan,Hess Daniel,Behe Martin,Schibli Roger,Moncayo Gerald,Frank Stephan,Hemmings Brian A.

Funder

Krebsliga beider Basel

Novartis Research Foundation

Publisher

Elsevier BV

Subject

Cell Biology

Reference43 articles.

1. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009;Dolecek;Neuro-Oncology,2012

2. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma;Bower;Cancer Chemother. Pharmacol.,1997

3. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme;Osoba;J. Clin. Oncol.,2000

4. Clinical relevance of MGMT in the treatment of cancer;Gerson;J. Clin. Oncol.,2002

5. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity;Hegi;J. Clin. Oncol.,2008

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cercosporamide, a polyketide-derived fungal metabolite, serves as an antifungal agent against phytopathogenic fungi;Mycoscience;2024-01-31

2. MNK: A Novel Promising Target for Cancer Immunotherapy;Current Medicinal Chemistry;2024-01-16

3. Dual targeting of Mcl-1 and Bcl-2 to overcome chemoresistance in cervical and colon cancer;Anti-Cancer Drugs;2023-11-13

4. Inhibition of Eukaryotic Initiating Factor eIF4E Overcomes Abemaciclib Resistance in Gastric Cancer;Current Medical Science;2023-09-27

5. Regulation of Eukaryotic Translation Initiation Factor 4E as a Potential Anticancer Strategy;Journal of Medicinal Chemistry;2023-09-19

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3